PEDIATRICS Vol. 114 No. 3 September 2004, pp. 703-707 (doi:10.1542/peds.2004-0178)
Low Molecular Weight Heparin in the Treatment of Venous and Arterial Thromboses in the Premature Infant
* Divisions of Pediatric Hematology and Oncology
Neonatology, Bristol Myers Squibb Children's Hospital at Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey
 |
ABSTRACT |
|---|
 TOP ABSTRACT METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Objective. Thrombosis in the preterm newborn is a growing problem, a result of improved survival of the smallest and sickest infants. Treatment with low molecular weight heparin (LMWH) has potential advantages, including predictable pharmacokinetics, subcutaneous administration, and minimal monitoring. However, studies with LMWH in term infants demonstrate the need for higher doses as compared with older children and adults. Physiologic differences suggest the need for gestational age–appropriate treatment strategies. Because of the relatively small numbers of infants affected each year, large-scale prospective studies have not been feasible. With the goal of establishing treatment guidelines within our own institution, we reviewed retrospectively our experience with LMWH for the treatment of thrombosis in the preterm infant.
Methods. Medical and pharmacy records of the intensive care nursery were used to identify preterm infants with venous and arterial thrombosis. Chart documentation, orders, pharmacy records, and radiologic studies were used to develop a retrospective database to assess efficacy and safety of the treatment. Main outcome measures were the dose of LMWH required for therapeutic levels, anti-factor Xa levels achieved, bleeding complications, resolution of thrombosis, additional thromboembolic events, and death from all causes.
Results. Ten preterm infants (mean gestational age: 26 weeks) who were treated with LMWH were identified. Mean patient weight at diagnosis of thrombosis was 1215 g (range: 565–1950 g). All 10 patients had either a current or recent history of a central venous or arterial catheter. Mean starting dose of enoxaparin was 1.25 mg/kg per 12 hours (range: 0.8–2 mg/kg). Therapeutic anti-factor Xa levels were achieved in only 5 patients. Mean time to therapeutic range was 33 days (range: 14–63 days). The mean dose of enoxaparin required to achieve therapeutic levels was 2.27 mg/kg per 12 hours (dose range: 2.0–3.5 mg/kg per 12 hours). Clot resolution was observed in all but 2 patients, both of whom died of complications of their thromboembolic events. No bleeding events that necessitated a change in treatment strategy occurred.
Conclusions. Higher doses of LMWH are required in the preterm infant as compared with the healthy term neonate. Once therapeutic levels are achieved, continued regular monitoring and dose adjustments are required to maintain anticoagulation in therapeutic range.
Key Words: anticoagulation • low molecular weight heparin • enoxaparin • thrombosis • premature • neonate • low birth weight infant
Abbreviations: UFH, unfractionated heparin • ATIII, anti-thrombin III • LMWH, low molecular weight heparin • ICN, intensive care nursery • IVH, intraventricular hemorrhage
The majority of thrombotic events in the pediatric population occur in neonates and infants who are younger than 2 years.1 Advances in neonatal care have led to increased survival of infants who are born as early as 23 weeks' gestation. These improvements have been facilitated by a reliance on indwelling catheters, which have resulted in an increased incidence of associated intravascular and intracardiac thrombus formation.
No guidelines currently exist for the management of neonatal arterial and venous thromboembolic events as treatments are largely extrapolated from experience in adults and older children. Although suggested doses have been published for anticoagulation2,3 and thrombolysis4 in term infants, experience in the premature infant is lacking. Recognition of physiologic disparities in the blood of the premature and term neonate emphasizes the need for gestational age–appropriate treatment strategies. Developmental differences in pharmacokinetics have an impact on choices of anticoagulants and how they are used and the doses required.5 Unfractionated heparin (UFH) is difficult to use in preterm infants because of the need for continuous infusion, frequent monitoring, and physiologically reduced levels of anti-thrombin III (ATIII). Fibrinolytic agents may increase the risk of intracranial hemorrhage and may not be optimally effective as a result of physiologically lower levels of plasminogen.6 Finally, surgical thrombectomy may be particularly risky in the extremely low birth weight infant.
Since 1996, we have used low molecular weight heparin (LMWH) in the intensive care nursery (ICN) for the treatment of arterial and venous thrombosis. LMWH was chosen because of the difficulty of administering and monitoring other anticoagulants in this age group. Potential advantages of LMWH include predictable pharmacokinetics, subcutaneous administration, and minimal monitoring. However, despite these benefits, there are no clear guidelines and few published data on how best to use this medication in the sick, premature neonate. In an attempt to establish treatment guidelines within our own institution, we reviewed retrospectively our experience with LMWH in the premature infant.
|
METHODS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Inpatient medical records of the ICN at the St Peter's University Hospital (an affiliated teaching hospital of the Robert Wood Johnson Medical School) for the period of July 1996 to August 2002 were reviewed to identify critically ill infants with thromboembolism. Pharmacy records were reviewed for the same period to identify infants who were treated with LMWH. Medical and pharmacy records, echocardiographic and radiologic reports, and laboratory results were used to develop a retrospective database to assess efficacy and safety of the treatment.
Main outcome measures were the dose of LMWH required for therapeutic levels, anti-factor Xa levels achieved, bleeding complications, resolution of thrombosis, additional thromboembolic events, and death from all causes. Therapeutic dosing of LMWH was defined as an anti-factor Xa level between 0.5 and 1.0 U/ml, and prophylactic dosing was defined as an anti-factor Xa range of 0.1 to 0.4 U/ml consistent with previously published sources.7
Permission to review the medical records was obtained from the University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School-Robert Wood Johnson University Hospital Institutional Review Board and the Committee for the Protection of Human Subjects in Research at the St Peter's University Hospital and Health System (Institutional Review Board #W-4075).
|
RESULTS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Thirteen neonates with catheter-associated thrombosis were identified. Of these 13 patients, 11 were treated with LMWH, 1 was treated with UFH and human tissue plasminogen activator, and 1 was treated with observation alone. All 11 infants who were treated with LMWH received enoxaparin. One infant was term and excluded from additional analysis. Characteristics of the 10 premature neonates who were treated with enoxaparin are shown in Table 1. Gestational ages were 24 to 34 weeks with a mean gestational age of 26 weeks. The age distribution of infants who received anticoagulant treatment ranged from 1 to 60 days (mean: 32 days). At the start of anticoagulation, mean patient weight was 1215 g (range: 565–1950 g).
|
In all cases, diagnosis of arterial or venous thrombosis was made on the basis of radiologic evaluation. In 9 patients, the diagnosis was made by demonstrating an echo dense mass in the heart or superior vena cava during an echocardiogram evaluation. In 1 patient, an aortic thrombus was seen on abdominal ultrasound. Ultrasound and echocardiogram evaluations were ordered for several specific indications, including evaluation for a patent ductus arteriosis, worsening respiratory status, heart failure, superior vena-caval syndrome, and suspected thrombosis as a result of thrombocytopenia. All 10 patients had either a current or a recent history of a central venous or arterial catheter. None had testing for an inherited or acquired thrombophilia.
Before starting anticoagulation, all patients had cranial ultrasonography. Nine patients were thrombocytopenic at diagnosis, with 8 requiring transfusions to maintain a platelet count >50 000/mm3. Therapy was monitored with weekly echocardiograms and head ultrasounds.
Anticoagulation was with enoxaparin. Because of the small doses required, a 30-mg/0.3 mL vial of enoxaparin was diluted with sterile water to a concentration of 20 mg/mL then refrigerated until use. Injections were given with a 25-G tuberculin needle, and sites were rotated to avoid skin breakdown. Blood was drawn 4 hours after an injection to measure anti-factor Xa activity. The frequency of measurement was at the discretion of the treatment team and differed for each patient. During this treatment period, anti-factor Xa levels were not available at the treating hospital. Frozen plasma samples were sent to the Blood Center of Southeastern Wisconsin (Milwaukee, WI) for measurement. Patient outcomes are shown in Table 2.
|
Bleeding
Four patients had a history of intracranial bleeding, including 1 with a grade III intraventricular hemorrhage (IVH), and 1 of retinal hemorrhage before starting anticoagulation. Resolution of hemorrhage was observed in all 5 patients. During treatment, 1 patient developed a small subependymal hemorrhage (anti-factor Xa level: 0.43 U/mL) and another an episode of epistaxis (anti-factor Xa level: 0.18 U/mL). In both cases, anticoagulation was continued without additional adverse events. In a third patient, postoperative wound bleeding (anti-factor Xa level: 0.50 U/mL) necessitated stopping LMWH for 36 hours.
Efficacy
Clot resolution was observed in all but 2 patients. Both of the patients with clot persistence or progression died of complications of their thromboembolic events. In 1 patient with worsening clot (patient 9), the anti-factor Xa was not known (enoxaparin dose: 2 mg/kg). In the second (patient 8), a therapeutic anti-factor Xa level was attained 63 days after starting treatment (enoxaparin: 2.1 mg/kg; anti-factor Xa: 0.72 U/mL), then decreased because of patient growth.
Level of Anticoagulation
Mean starting dose of enoxaparin was 1.25 mg/kg per 12 hours (range: 0.8–2.0 mg/kg). A total of 28 measurements of anti-factor Xa were documented among the 10 patients. Therapeutic anti-factor Xa levels were achieved in 5 patients. Mean time to therapeutic range was 33 days (range: 14–63 days). Four of the remaining 5 patients had documented anti-factor Xa levels in the prophylactic range (0.1–0.4 U/mL). Anti-factor Xa levels could not be found for the last patient. Only 2 patients did not attain a level of 0.2 U/mL or higher after the first dose of LMWH. The observed dose ranges to achieve therapeutic and prophylactic anti-factor Xa levels are shown in Table 3. The data were divided to determine whether the required doses needed to achieve either therapeutic or prophylactic levels varied with patient weight. The mean dose for infants who weighed 500 to 1000 g compared with those who weighed 1000 g or greater was similar for both therapeutic (P = .4; standard deviation: 0.5) and prophylactic (P = .3; standard deviation: 0.3) levels.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Newborns constitute the single largest group of children who are diagnosed with thromboembolic complications. Although an increasingly common complication in the tertiary care nursery, thrombosis remains a relatively rare event. The incidence of symptomatic thrombosis is
5.1 per 100 000 live births8 and 2.4 per 1000 neonatal intensive care admissions.9 Treatment options include supportive care, anticoagulation, thrombolysis, and surgery. Several treatment registries currently exist,8–10 but none has been sufficient to determine the benefits of any one particular option over the others. Management decisions seem to be highly individualized, reflecting local preferences and the heterogeneous nature of the specific events reported. How best to treat these sick neonates remains an unanswered question. Because of the relatively small numbers of infants affected each year, determining the optimal therapeutic approach to these patients inevitably will require large, multicenter, collaborative studies. Among infants with thrombosis, mortality rates are the highest for those with aortic or central venous line–associated thrombosis involving the right atrium or superior vena cava.9 All of our patients in this study had thromboses in 1 of these locations, driving the decision to start anticoagulation. Our decision to use LMWH was made because subcutaneous injection obviates the requirement of dedicated intravenous access and there is less need for laboratory monitoring as compared with UFH. We chose to avoid thrombolytic therapy due to concerns of precipitating hemorrhagic complications, because most patients were thrombocytopenic and required platelet transfusion and several had a history of intracranial or retinal hemorrhage or had recent surgery.
Dosing recommendations for LMWH in term infants have been published.2,3 In infants who weigh <5 kg and are younger than 2 months, the current recommended starting dose of enoxaparin is 1.5 mg/kg per 12 hours, as compared with the adult recommended dose of 1 mg/kg per 12 hours. Studies with UFH and LMWH in young children and in the porcine model11 demonstrate that younger patients require higher doses as a result of accelerated clearance of these drugs and from lower levels of ATIII.12 ATIII levels are lower in preterm than in comparatively aged term infants,13 and renal clearance mechanisms are not yet fully developed,14 so it is probable that UFH and LMWH doses will be different in this particular group.
The possibility that preterm infants require higher doses of LMWH was suggested by a report of 2 neonates who were <28 weeks' gestational age with multiple medical problems and extensive central line–related thrombosis who required >3 mg/kg per 12 hours of enoxaparin to achieve the targeted anti-factor Xa.15 In our study, the average dose required to achieve therapeutic levels was 2.2 mg/kg per 12 hours; however, 1 patient required 3.5 mg/kg per 12 hours and a second infant's anti-factor Xa remained subtherapeutic despite 2.5 mg/kg per 12 hours. Only 5 of the 10 patients had therapeutic levels documented during the treatment period. On the basis of this experience, we have modified our practice to start anticoagulation with enoxaparin at 2 mg/kg per 12 hours. In many sick preterm infants, this starting dose will not be sufficient to achieve target anti-factor Xa levels, thus emphasizing the need for aggressive monitoring in the first days of treatment to avoid long delays in achieving adequate anticoagulation.
Although 1 of the benefits of using LMWH is a decreased need for monitoring, it is evident that ongoing measurement of anti-factor Xa levels is still necessary in this population. Once therapeutic levels are achieved, continued regular monitoring and dose adjustments are still needed. In this study, only 1 patient (patient 2) had anti-factor Xa levels stable in the therapeutic range 100% of the time, but this patient required the shortest course of anticoagulation of all of the infants studied. Primary reasons identified for anti-factor Xa levels dropping outside the therapeutic range were 1) infrequent monitoring and 2) rapid patient growth. As a result of these findings, we recommend that anti-factor Xa levels be reassessed once a week at a minimum—still a considerable improvement over UFH, which requires daily or more frequent monitoring. Simple correction of the dose of LMWH for changes in weight may not be adequate, as there is evidence that LMWH may accumulate in the body over time.7
The incidence of intracranial hemorrhage among infants with a birth weight <1500 g is 25%,16 raising questions regarding the safety of anticoagulation in the ICN. The lack of aggressive anticoagulation seen in our study may in part reflect unease by the neonatologists. Such concern is reasonable in the face of a possible increased risk of IVH in low birth weight infants who receive UFH to maintain patency of vascular catheters.17–19 Although no strong conclusions regarding safety of LMWH in the ICN can be made from our data, it can be pointed out that no patients incurred bleeding events that necessitated a change in treatment plan. One patient did develop a subependymal bleed during treatment, but the lesion was small and did not change during the remainder of the course of therapy. Three patients had ultrasound findings of concurrent intracranial hemorrhage at the start of anticoagulation, including 1 with superior vena caval occlusion and grade III IVH. None of these 3 patients experienced progression of their intracranial hemorrhage, and all had resolution of their abnormal ultrasound findings while receiving LMWH. Notably, 2 of these patients did attain anti-factor Xa levels in therapeutic range. In contrast, 2 patients with either undocumented or subtherapeutic anti-factor Xa levels died of clot progression, illustrating the risks associated with nonaggressive treatment of neonatal arterial and venous thromboembolic events.
The strength of the conclusions presented in this article are constrained by both the small number of patients observed and the retrospective study design. Despite these limitations, our findings are similar to those recently published in a prospective cohort study of unselected newborn infants who were treated with LMWH. Among 15 infants who were <37 weeks' gestation, the average dose of enoxaparin required to maintain therapeutic range was 2.1 mg/kg per 12 hours, and therapeutic levels were attained in only 50% of measurements.20 The results of these studies suggest that our clinical experience with LMWH in the preterm infant is consistent with that encountered at other institutions. We propose that these observations provide a starting point for future randomized collaborative treatment studies to define better the appropriate dosing and treatment protocols for preterm neonates with thrombosis.
|
ACKNOWLEDGMENTS |
|---|
This project was supported in part by an Unrestricted Educational Grant from Aventis.
|
FOOTNOTES |
|---|
Accepted Mar 5, 2004.
Reprint requests to (L.A.M.) Cancer Institute of New Jersey, 195 Little Albany St, New Brunswick, NJ 08901. E-mail: michaela{at}umdnj.edu
Dr Michaels received an Unrestricted Educational Grant from Aventis.
"Today, in some suburbs, breast implants are a popular gift for high school graduates."
Goodman E. Boston Globe. October 31, 2003
Submitted by Student
|
REFERENCES |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
- Andrew M, David M, Adams M, et al. Venous thromoboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE.
Blood. 1994;83
:1251
–1257
[Abstract/Free Full Text] - Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low molecular weight heparin in pediatrics patients with thrombotic disease: a dose finding study. J Pediatr. 1996;128 :313 –318[CrossRef][Web of Science][Medline]
- Massicotte P, Julian JA, Marzinotto V, et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res. 2003;109 :93 –99[CrossRef][Web of Science][Medline]
- Farnoux C, Camard O, Pinquier D, Hurtaud-Roux MF, et al. Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. J Pediatr. 1998;133 :137 –140[CrossRef][Web of Science][Medline]
- Williams MD, Chalmers EA, Gibson BES. Guidelines: the investigation and management of neonatal hemostasis and thrombosis. Br J Haematol. 2002;119 :295 –309[CrossRef][Web of Science][Medline]
- Andrew M, Brooker L, Leaker M, Paes B, Weitz J. Fibrin clot lysis by thromboembolic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost. 1992;68 :325 –330[Web of Science][Medline]
- Hirsh J. Low Molecular Weight Heparins. Monograph. Hamilton, Ontario, Canada: Decker Periodicals Inc; 1994
- Nowak-Gottl U, von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey.
Arch Dis Child Fetal Neonatal Ed. 1997;76
:F163
–F167
[Abstract/Free Full Text] - Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry.
Pediatrics. 1995;96
:939
–943
[Abstract/Free Full Text] - Von Ommen CH, Heijboer H, Buller HR, Hirasing RW, Heijmans SA, Peters M. Venous thromboembolism in childhood: a prospective two year registry in The Netherlands. J Pediatr. 2001;139 :676 –681[CrossRef][Web of Science][Medline]
- Andrew M, Ofosu F, Brooker L, et al. The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig. Thromb Res. 1989;56 :529 –539[CrossRef][Web of Science][Medline]
- Andrew M. Developmental hemostasis: relevance to hemostatic problems during childhood. Semin Thromb Hemost. 1995;2 :341 –356
- Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990;12 :95 –104[Web of Science][Medline]
- Alcore J, McNamera PJ. Pharmacokinetics in the newborn. Adv Drug Del Rev. 2003;29 :667 –686[CrossRef]
- Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr. 2000;136 :439 –445[CrossRef][Web of Science][Medline]
- Phillip AG, Allan WC, Tito AM, Wheeler LR. Intraventricular hemorrhage in preterm infants: declining incidence in the 1980's.
Pediatrics. 1989;84
:797
–801
[Abstract/Free Full Text] - Lesko SM, Mitchell AA, Epstein MF, Louis C, Giacola GP, Shapiro S. Heparin use as a risk factor for intraventricular hemorrhage in low birth weight infants. N Engl J Med. 1986;314 :1156 –1160[Abstract]
- Malloy MH, Cutter GR. The association of heparin exposure with intraventricular hemorrhage among very low birth weight infants. J Perinatol. 1995;15 :185 –191[Medline]
- Chang GY, Lueder FL, DiMichele DM, Radkowski MA, McWilliams LJ, Jansen RD. Heparin and the risk of intraventricular hemorrhage in premature infants. J Pediatr. 1997;131 :362 –366[Web of Science][Medline]
- Streif W, Goebel G, Chan AKC, Massicotte MP. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.
Arch Dis Child Fetal Neonatal Ed. 2003;88
:F365
–F370
[Abstract/Free Full Text]
PEDIATRICS (ISSN 1098-4275). ©2004 by the American Academy of Pediatrics
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  K. V. Lunsford, A. J. Mackin, V. C. Langston, and M. Brooks Pharmacokinetics of Subcutaneous Low Molecular Weight Heparin (Enoxaparin) in Dogs J. Am. Anim. Hosp. Assoc., November 1, 2009; 45(6): 261 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Goldenberg Thrombophilia States and Markers of Coagulation Activation in the Prediction of Pediatric Venous Thromboembolic Outcomes: A Comparative Analysis with Respect to Adult Evidence Hematology, January 1, 2008; 2008(1): 236 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Butler-O'Hara, C. J. Buzzard, L. Reubens, M. P. McDermott, W. DiGrazio, and C. T. D'Angio A Randomized Trial Comparing Long-term and Short-term Use of Umbilical Venous Catheters in Premature Infants With Birth Weights of Less Than 1251 Grams Pediatrics, July 1, 2006; 118(1): e25 - e35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ramasethu Management of Vascular Thrombosis and Spasm in the Newborn NeoReviews, June 1, 2005; 6(6): e298 - e311. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
